Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Advanced provider by MediFind in the treatment of Rosai-Dorfman Disease. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of Rosai-Dorfman Disease. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Janis Taube is a professor of dermatology and pathology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Her area of clinical expertise is dermatopathology. Dr. Taube serves as the Director of the Division of Dermatopathology and as the Assistant Director of the Dermatoimmunology Laboratory at the School of Medicine. Dr. Taube received her undergraduate degree in engineering from Duke University. She earned her M.D. from Tulane University and her M.Sc. in molecular medicine from University College London. She completed her residency in pathology at Johns Hopkins where she also served as the chief resident, before undertaking a dermatopathology fellowship at Stanford University. In 2009, Dr. Taube returned to Johns Hopkins for her certification in the Melanoma Clinic. She is one of the lead scientific researchers in the Department of Dermatology at Johns Hopkins. She has written over 180 peer-reviewed publications, and her research has been cited over 70,000 times. In addition to running her own research laboratory, she serves as the co-Director of the Mark Foundation Center for Advanced Genomics and Imaging and also as the co-Director of the Tumor Microenvironment Core Laboratory for the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Dr. Taube is rated as an Experienced provider by MediFind in the treatment of Rosai-Dorfman Disease. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Basal Cell Skin Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Pancreaticoduodenectomy.

Dr. Francis Deng is an expert in neuroradiology, specializing in diagnostic imaging of the head, neck, brain, and spine. He is a magna cum laude graduate of Harvard College and earned his medical degree from Washington University in St. Louis School of Medicine. He then completed a medical internship at the Brigham and Women's Hospital, followed by diagnostic radiology residency and neuroradiology fellowship at Massachusetts General Hospital, both affiliates of Harvard Medical School. Dr. Deng is a recognized educator both locally and internationally. He has authored chapters in bestselling textbooks such as First Aid for the USMLE Step 1 and Core Radiology: A Visual Approach to Diagnostic Imaging. He is an Editor of Radiopaedia.org and was Co-Convener of the Radiopaedia 2024 Virtual Conference, which had more than 13,000 registrants globally. With Medality (MRI Online), he was core faculty for the Fellowship Certificate programs on Brain & Spine Neuroradiology and for Stroke Imaging. For several high-impact radiology journals, Dr. Deng has received distinguished reviewer awards and served in editorial roles. He was a Visiting Scholar with the American Board of Medical Specialties in 2023-2024 and, as a student, served on the Board of Directors of the National Resident Matching Program. Dr. Deng has an academic interest in diagnostic excellence and error. Locally, he holds regular quality assurance conferences for radiology residents to learn from misses and misinterpretations. He hosted a podcast series on this topic published under the aegis of the American Journal of Roentgenology. He also serves as an expert witness in medical liability/malpractice cases. Dr. Deng is rated as an Experienced provider by MediFind in the treatment of Rosai-Dorfman Disease. His top areas of expertise are Morgagni-Stewart-Morel Syndrome, Cavernous Sinus Thrombosis, Lemierre Syndrome, Familial Otosclerosis, and Thrombectomy.

Dr. Zambidis is Associate Professor of Oncology and Pediatrics at the Johns Hopkins University School of Medicine, and a member of the Johns Hopkins Kimmel Cancer Center. Dr. Zambidis’ clinical expertise is in the treatment of disorders of the immune system, histiocytic disorders, hematologic malignancies, blood and bone marrow transplantation (BMT), and regenerative medicine. His research interest focuses on advancing our understanding of pluripotent stem cells– the ‘master’ stem cells that can generate any new cell or tissue that the body needs to repair itself. Dr. Zambidis earned his M.D./Ph.D. in the Medical Scientist Training Program at the University of Rochester, Rochester, N.Y. He completed his Pediatrics Residency in the Department of Pediatrics, Washington University, St. Louis, Missouri, and his clinical/research fellowships in Pediatric Hematology/Oncology at the Johns Hopkins Hospital and the National Cancer Institute at the NIH. Dr. Zambidis has been interested in the biology of stem cells since he came to Johns Hopkins, in 2001. As a Pediatric Hematology/Oncology fellow, he was one of the very first Hopkins investigators to work with human embryonic stem cells (hESCs), beginning shortly after they were made available to the biomedical research community, in 2002. Dr. Zambidis was awarded the first NIH K08 Clinician-Scientist Training Award specifically investigating the therapeutic potential of human pluripotent stem cells (2004). After joining the Hopkins faculty, in 2005, he developed an experimental model of the early formation process of human blood and blood vessels using human pluripotent stem cells. The Zambidis laboratory at the Johns Hopkins Institute for Cell Engineering focuses on understanding the developmental biology of human hemato-vascular and human pluripotent stem cells. More recently, his group completed studies on highly efficient methods for generating nonintegrated, human induced pluripotent stem cell (hiPSC) lines from myeloid progenitors. His group has developed novel hiPSC-based vascular therapies for retinopathies, and more recently derived a new class of human pluripotent stem cells in a naïve ground state with new functionalities with even greater potency and stronger regenerative capacities. As a BMT physician-scientist, his long-term goal is to use hESC, hiPSC, and related pluripotent stem cell technologies to not only treat severe degenerative diseases, but also to elucidate the biological nature of cancer and aging. Dr. Zambidis is rated as an Experienced provider by MediFind in the treatment of Rosai-Dorfman Disease. His top areas of expertise are Gaucher Disease, Reticulohistiocytoma, Rosai-Dorfman Disease, and Lymphofollicular Hyperplasia.

David Sill is a Radiologist and an Interventional Radiologist in Baltimore, Maryland. Dr. Sill is rated as an Experienced provider by MediFind in the treatment of Rosai-Dorfman Disease. His top areas of expertise are Retroperitoneal Fibrosis, Intussusception in Children, Nonalcoholic Steatohepatitis (NASH), and Visceromegaly.

Megan Askew is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Askew is rated as an Experienced provider by MediFind in the treatment of Rosai-Dorfman Disease. Her top areas of expertise are Hemolytic Crisis, Sickle Cell Disease, Alpha Thalassemia X-Linked Intellectual Disability Syndrome, and Alpha Thalassemia. Dr. Askew is currently accepting new patients.

Jonathan Powell is an Oncologist in Baltimore, Maryland. Dr. Powell is rated as an Experienced provider by MediFind in the treatment of Rosai-Dorfman Disease. His top areas of expertise are Reticulohistiocytoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Rosai-Dorfman Disease.

Dakara Wright is a Dermatologist in Halethorpe, Maryland. Dr. Wright is rated as an Experienced provider by MediFind in the treatment of Rosai-Dorfman Disease. Her top areas of expertise are Hidradenitis Suppurativa, Atopic Dermatitis, Autosomal Recessive Hypotrichosis, and Alopecia Areata. Dr. Wright is currently accepting new patients.

Dr. Ronald Sweren is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous lymphoma/mycosis fungoides, phototherapy/ photopheresis and melanoma. Dr. Sweren also serves as director of the Phototherapy/Photopheresis Program in the Department of Dermatology. Dr. Sweren earned his M.D. from the University of Maryland School of Medicine. He completed his residency in dermatology at University of Maryland Medical Center and in pediatrics at Sinai Hospital of Baltimore. Dr. Sweren is rated as an Experienced provider by MediFind in the treatment of Rosai-Dorfman Disease. His top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), Melanoma, and T-Cell Lymphoma.